BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,059 filers reported holding BAXTER INTL INC in Q1 2018. The put-call ratio across all filers is 0.59 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $72 | -31.4% | 2,150 | -12.2% | 0.02% | -32.4% |
Q1 2024 | $105 | +10.5% | 2,450 | 0.0% | 0.04% | +2.8% |
Q4 2023 | $95 | +3.3% | 2,450 | 0.0% | 0.04% | -7.7% |
Q3 2023 | $92 | -17.9% | 2,450 | 0.0% | 0.04% | -11.4% |
Q2 2023 | $112 | +8.7% | 2,450 | -3.9% | 0.04% | 0.0% |
Q1 2023 | $103 | -20.8% | 2,550 | 0.0% | 0.04% | -25.4% |
Q4 2022 | $130 | -99.9% | 2,550 | -1.9% | 0.06% | -14.5% |
Q3 2022 | $140,000 | -16.2% | 2,600 | 0.0% | 0.07% | -11.5% |
Q2 2022 | $167,000 | -17.3% | 2,600 | 0.0% | 0.08% | 0.0% |
Q1 2022 | $202,000 | -9.4% | 2,600 | 0.0% | 0.08% | -1.3% |
Q4 2021 | $223,000 | +6.7% | 2,600 | 0.0% | 0.08% | -2.5% |
Q3 2021 | $209,000 | +10.6% | 2,600 | +10.6% | 0.08% | +14.1% |
Q2 2021 | $189,000 | -4.5% | 2,350 | 0.0% | 0.07% | -6.6% |
Q1 2021 | $198,000 | +2.6% | 2,350 | -2.1% | 0.08% | -2.6% |
Q4 2020 | $193,000 | -1.0% | 2,400 | -1.0% | 0.08% | -10.3% |
Q3 2020 | $195,000 | -6.7% | 2,425 | -3.0% | 0.09% | -9.4% |
Q4 2019 | $209,000 | -4.6% | 2,500 | 0.0% | 0.10% | -14.3% |
Q3 2019 | $219,000 | +7.4% | 2,500 | 0.0% | 0.11% | +5.7% |
Q2 2019 | $204,000 | 0.0% | 2,500 | 0.0% | 0.11% | -0.9% |
Q1 2019 | $204,000 | +12.7% | 2,500 | 0.0% | 0.11% | +7.0% |
Q4 2018 | $181,000 | -61.6% | 2,500 | -59.0% | 0.10% | -59.7% |
Q3 2018 | $471,000 | +4.4% | 6,100 | 0.0% | 0.25% | -4.2% |
Q2 2018 | $451,000 | +13.6% | 6,100 | 0.0% | 0.26% | +7.0% |
Q1 2018 | $397,000 | +0.5% | 6,100 | 0.0% | 0.24% | +7.6% |
Q4 2017 | $395,000 | -99.9% | 6,100 | 0.0% | 0.22% | -5.5% |
Q3 2017 | $382,775,000 | +3.7% | 6,100 | 0.0% | 0.24% | +0.8% |
Q2 2017 | $369,294,000 | +15.2% | 6,100 | 0.0% | 0.24% | +15.7% |
Q1 2017 | $320,555,000 | +88696.4% | 6,100 | -23.0% | 0.20% | -11.3% |
Q4 2016 | $361,000 | -2.2% | 7,926 | 0.0% | 0.23% | -4.6% |
Q2 2016 | $369,000 | +6.6% | 7,926 | -0.9% | 0.24% | +10.6% |
Q1 2016 | $346,000 | +15.7% | 7,995 | 0.0% | 0.22% | +1.4% |
Q4 2015 | $299,000 | +9.9% | 7,995 | -3.6% | 0.22% | -0.9% |
Q3 2015 | $272,000 | -53.1% | 8,295 | 0.0% | 0.22% | -48.6% |
Q2 2015 | $580,000 | +2.1% | 8,295 | 0.0% | 0.42% | +1.9% |
Q1 2015 | $568,000 | -6.6% | 8,295 | 0.0% | 0.41% | -4.6% |
Q4 2014 | $608,000 | +2.2% | 8,295 | 0.0% | 0.43% | -2.9% |
Q3 2014 | $595,000 | -0.8% | 8,295 | 0.0% | 0.45% | -0.9% |
Q2 2014 | $600,000 | -1.6% | 8,295 | 0.0% | 0.45% | -4.4% |
Q1 2014 | $610,000 | +3.9% | 8,295 | -1.8% | 0.47% | +4.7% |
Q4 2013 | $587,000 | +7.7% | 8,445 | +1.8% | 0.45% | -1.7% |
Q3 2013 | $545,000 | -5.1% | 8,295 | 0.0% | 0.46% | -9.5% |
Q2 2013 | $574,000 | – | 8,295 | – | 0.51% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Soditic Asset Management LLP | 147,620 | $7,951,000 | 9.91% |
NUANCE INVESTMENTS, LLC | 5,429,702 | $292,444,000 | 6.51% |
Endurant Capital Management LP | 245,093 | $13,201,000 | 4.30% |
Veritas Asset Management LLP | 8,589,401 | $462,625,000 | 3.83% |
GENERATION INVESTMENT MANAGEMENT LLP | 11,876,040 | $639,644,000 | 3.80% |
Sivik Global Healthcare LLC | 120,000 | $6,463,000 | 3.59% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 480,500 | $25,880,000 | 3.31% |
Integral Health Asset Management, LLC | 300,000 | $16,158,000 | 3.14% |
Boothe Investment Group, Inc. | 89,078 | $4,798,000 | 3.11% |
Glenview Capital Management | 2,257,019 | $121,563,000 | 3.04% |